• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Stock chart, upward arrow

Biggest gainers and losers for the week of Nov. 8-12, 2021

Nov. 12, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More
Handshake behind digital globe

Med-tech M&As in 2021 valued at $112B

Nov. 12, 2021
By Karen Carey
Without a doubt, 2021 has been a strong year for med-tech M&As, which are valued at significantly more than each of the three prior years. The industry has completed 520 M&As worth $111.7 billion so far, which is 88% more than the next highest year, 2019’s $59.48 billion. The volume is 33% more than the 391 M&As completed in 2020. In addition to completed M&As, a total of 1,376 med-tech deals, including licensings, collaborations and joint ventures, have been completed. They are valued at $1.98 billion, with only 31 deals including financial terms. The number of med-tech deals this year are only slightly below the 1,400 completed by the end of the year in 2020.
Read More

Med-tech gainers and losers for Nov. 8-12, 2021

Nov. 12, 2021
The top 10 med-tech stock gainers and losers for the week.
Read More
Cancer cell and DNA

Cancer index remains low on safety issues and BLA withdrawal

Nov. 10, 2021
By Karen Carey
Continuing its downward trend, BioWorld’s Cancer Index (BCI) has fallen by 19.16% this year, a stark contrast with the broader Nasdaq Biopharmaceutical Index and the Dow Jones Industrial Average, both of which are tracking up by 4.49% and 19.03%, respectively.
Read More
Gold wireframe handshake

Biopharma deals in 2021 on track to beat top year

Nov. 8, 2021
By Karen Carey
A surge in deal activity over the last few months has placed 2021 in the running for beating 2020, the best year on record, and becoming the top year for the biopharma industry to date. BioWorld has recorded 1,680 deals valued at $167.39 billion in 2021 vs. 1,744 deals valued at $159.98 billion by this point last year. That puts 2021 ahead by about 5% on deal values.
Read More
Stock chart, upward arrow

Biggest gainers and losers for the week of Nov. 1-5, 2021

Nov. 5, 2021
The top 10 biopharma stock gainers and losers for the week.
Read More

BioWorld and Nasdaq stock indices

Nov. 5, 2021
These graphs compare the performance of the biotech stocks for all of 2021 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More
Hand holding IPO, financial icons

Biopharma money raised by quarter in 2021 (US$M)

Nov. 5, 2021
Biopharma money raised to-date and by quarter in 2021, including public, private and other financings.
Read More

Biopharma money raised: Jan. 1-Nov. 4, 2021

Nov. 5, 2021
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2021 vs. 2020 vs. 2019

Nov. 5, 2021
Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.
Read More
Previous 1 2 … 153 154 155 156 157 158 159 160 161 … 264 265 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe